Default company panoramic image


Defymed develops and markets innovative bioartificial medical devices for therapeutic use with a first focus on type 1 diabetes.

  • Stage Product In Development
  • Industry Biotechnology
  • Location Strasbourg, Alsace, France
  • Currency EUR
  • Founded March 2011
  • Employees 3
  • Website

Company Summary

Defymed® develops an implantable bio-artificial pancreas, named MAILPAN (MAcro-encapsulation of PANcreatic Islets) to treat type 1 diabetic patients. In the future other products will target other therapies such as bioartificial liver and bioartificial kidney. Defymed® is a spin-off of the CeeD (Centre europeen d’étude du Diabète de Strasbourg) which has been working on an innovative concept of a bio-artificial pancreas since 1996.


  • Default avatar
    Séverine Sigrist

    PhD in sciences from Louis Pasteur University in Strasbourg.She is also the head of the research department of the «Centre europeen d’etude du Diabète (CeeD)» since 2005, where she focuses on the discovery of innovative therapies for diabetes treatment. She has worked on the development of the MAILPAN® since more than ten years at the CeeD. She insures Defymed's development by searching for academic/industrial partners and seed funds, following t

  • Default avatar
    Richard Bouaoun
    R&D Manager

    After a doctorate in Molecular Biology applied to immunology, he followed master studies in innovative projects management at the Management School of Strasbourg. As a former project manager at the Alsace’s incubator, SEMIA, he followed up MAILPAN®’s project and has joined DEFYMED®’s team since March 2011. He is in charge of the coordination of MAILPAN®’s scientific program, the following of the clinical and regulatory affairs and the establishm


  • Default avatar
    Cabinet ORION - Strasbourg
    Default avatar
    Thierry Mignot - CeeD - Strasbourg

Previous Investors

  • Default avatar